Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
- 26 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (1), 87-94
- https://doi.org/10.1007/s00259-020-04914-8
Abstract
Purpose To evaluate the clinical value of 68Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer (BCR). Methods One hundred three BCR patients (median age, 70 years; median PSA, 0.47 ng/mL) with negative 68Ga-PSMA PET/CT, followed up for at least 1 year, were retrospectively identified in a database of 1003 consecutive patients undergoing 68Ga-PSMA PET/CT for BCR. Clinical recurrence (CR) was determined or excluded on follow-up imaging selected as per clinical practice. Clinical recurrence-free survival (CRFS) was computed from the date of negative 68Ga-PSMA PET/CT to the date of evident disease; frequencies of CRFS were described as per ISUP patient subset (subset 1: ISUP grades 1 and 2; subset 2: ISUP grade 3; subset 3: ISUP grades 4 and 5) and other conventional variables. Results In 57 patients out of 103 (55.3%), CR was detected in the prostatic fossa (45.6%), nodes (38.6%), and bone (15.8%). The median CRFS was 15.4 months (range, 12.1–20.5), with a CRFS at 12 months in 61.4% of cases (range, 50.9–70.4) whereas the 24-month CRFS was 34.8% (range, 24–45.8). ISUP subset 1 benefited from significantly longer CRFS compared to subset 2 and subset 3 (median CRFS, 20.5 months, 12.6 months, and 12.1 months, respectively). ISUP subset 3 had significantly poorer 24-month CRFS (9.3%) compared to subset 1 (47.8%) and subset 2 (33.5%). At the univariate and multivariate analyses, the ISUP subset was the only significant risk factor for clinical relapse; ISUP subset 3 and subset 2 patients held a higher risk of CR compared to subset 1 patients (HR of 2.75 [1.35–5.57] for subset 3 versus subset 1; HR of 2.08 [1.11–3.88] for subset 2 versus subset 1). Conclusion 68Ga-PSMA PET/CT negativity in early BCR patients (PSA < 0.5 ng/mL) with low-grade primary prostate cancer (ISUP1 and 2) may support the exploration of a clinical surveillance approach in future prospective studies.Keywords
Funding Information
- Ministero della Salute (RF-2016-02364230)
- Associazione Italiana per la Ricerca sul Cancro (IG 20476)
This publication has 22 references indexed in Scilit:
- Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate CancerJournal of Clinical Oncology, 2016
- Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate CancerPharmaceuticals, 2014
- Early Salvage Radiotherapy Following Radical ProstatectomyEuropean Urology, 2014
- Salvage radiotherapy after prostatectomy – What is the best time to treat?Radiotherapy and Oncology, 2012
- The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐upBJU International, 2011
- Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical ProstatectomyJournal of Clinical Oncology, 2007
- Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical ProstatectomyJAMA, 2005
- Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapyBJU International, 2004
- Salvage Radiotherapy for Recurrent Prostate Cancer After Radical ProstatectomyJAMA, 2004
- Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissuesUrologic Oncology, 1995